Kato M, Yuki N, Kaneko A, Yamamoto K, Kasahara A, Masuzawa M, Hayashi N
Department of Gastroenterology, Osaka National Hospital.
Nihon Rinsho. 2001 Jul;59(7):1315-9.
In almost all patients in whom interferon(IFN) treatment dose not result in persistent negative findings for HCV-RNA, HCV-RNA levels show a rebound after discontinuing the administration. In most patients, HCV-RNA levels after administration are increased compared to pretreatment values. When a rapid increase in HCV-RNA levels causes transient exacerbation of transaminase levels, HCV-RNA levels then rapidly decrease. In two-step interferon rebound therapy(TIRT), IFN is additionally administered when HCV-RNA levels are decreased. We previously reported that TIRT was useful for treating type 1b patients with an HCV-RNA level of 1 Meq/ml or more who did not respond to IFN treatment. In the year 2000, health insurance covered the additional administration of IFN. The use of TIRT for additional administration may further improve treatment response in patients who do not respond to IFN treatment.
在几乎所有接受干扰素（IFN）治疗但HCV-RNA未持续呈阴性结果的患者中，HCV-RNA水平在停止给药后会出现反弹。在大多数患者中，给药后的HCV-RNA水平较治疗前值有所升高。当HCV-RNA水平快速升高导致转氨酶水平短暂恶化时，HCV-RNA水平随后会迅速下降。在两步干扰素反弹疗法（TIRT）中，当HCV-RNA水平下降时额外给予IFN。我们之前报道过，TIRT对治疗HCV-RNA水平为1 Meq/ml或更高且对IFN治疗无反应的1b型患者有用。在2000年，医疗保险涵盖了IFN的额外给药。将TIRT用于额外给药可能会进一步改善对IFN治疗无反应患者的治疗反应。
